Enhanced dissolution of Oxcarbazepine microcrystals using a static mixer process

Colloids and Surfaces B: Biointerfaces

Volumn 59, Issue 2, 2007, Pages 208-214

  Douroumis, D ^a   Fahr, A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Dissolution enhancement; Microcrystals; Poorly soluble drugs; Static mixer

Indexed keywords

DATA REDUCTION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; INFRARED SPECTROSCOPY; PRECIPITATION (CHEMICAL);

DISSOLUTION ENHANCEMENT; POORLY SOLUBLE DRUGS; STATIC MIXER;

MICROCRYSTALS;

OXCARBAZEPINE;

AQUEOUS SOLUTION; ARTICLE; CRYSTAL; DEVICE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROMETRY; PARTICLE SIZE; POWDER; PRECIPITATION; PRIORITY JOURNAL; PROCESS DESIGN; STATIC MIXER; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CRYSTALLIZATION; PARTICLE SIZE; POWDERS; PRECIPITATION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 34547676365     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2007.05.009     Document Type: Article

References (24)

1. Amidon G.L., Lunnernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Amidon G.L., and Löbenberg R. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
3. Martinez M., Augsburger L., Johnston T., and Jones W.W. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I. Biopharmaceutics and formulation considerations. Adv. Drug Deliv. Rev. 54 (2002) 805-824
4. Noyes A.S., and Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
5. Rasenack N., Steckel H., and Müller B.W. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J. Pharm. Sci. 92 (2003) 35-44
6. Rasenack N., Hartenhauer H., and Müller B.W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 254 (2003) 137-145
7. Rogers T.L., Nelsen A.C., Hu J., Brown J.N., Sakrari M., Young T.J., Johnston K.P., and Williams III R.O. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Biopharm. 54 (2002) 271-280
8. Horn D., and Lüddecke E. In: Pelizzetti E. (Ed). Fine Particles Science and Technology-From Micro to Nanoparticles (1996), Kluwer, Dordrecht 761-775
9. Mahajan A.J., and Kirwan D.J. Rapid precipitation of biochemicals. J. Phys. D Appl. Phys. 26 (1993) B176-B180
10. B. Kühn, Verfahren und Vorrichtung zur In-Situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation, German Patent No. WO 99/32175 A1 (1999).
11. Jürgens K., and Müller B.W. A new formulation concept with drugs with poor water soloubility for parenteral application. Pharmazie 60 (2005) 665-670
12. Gassmann P., List M., Schweitzer A., and Sucker H. Hydrosols-alternatives for the parenteral application of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 40 (1994) 64-72
13. Douroumis D., and Fahr A. Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur. J. Pharm. Biophys. 63 (2006) 173-175
14. Baldyga J., and Bourne J.R. Turbulent Mixing and Chemical Reactions (1999), Wiley, Chichester
15. P.H. Stahl, Novartis-Pharmaceutische Entwicklung, 1972.
16. Rasenack N., and Müller B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 19 (2002) 1894-1900
17. Chang S.A., and Gray D.G. The surface tension of aqueous hydroxypropyl cellulose solutions. J. Colloid Interface Sci. 67 (1978) 255-1265
18. Law S.L., and Kayes J.B. Absorption of non-anionic water soluble cellulose polymers at the solid water interface and their effect on suspension stability. Int. J. Pharm. 15 (1983) 251-260
19. Müller B.J., Leuenberger H., and Kissel T. Albumine nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm. Res. 13 (1996) 32-37
20. Tsai D.C., Howard S.A., Hogan T.F., Malanga C.J., Kandzari S.J., and Ma J.K.H. Preparation and in vitro evaluation of polylactic acidmitomycin C microscapsules. J. Microencapsul. 3 (1986) 191-193
21. Konan Y.N., Cerny R., Favet J., Berton M., Gurnya R., and Allemann E. Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur. J. Pharm. Biopharm. 55 (2003) 115-124
22. Barzegar-Jalali M., Nayebi A.M., Valizadeh1 H., Hanaee J., Barzegar-Jalali A., Adibkia K., Anoush M., and Sistanizad M. Evaluation of in vitro-in vivo correlation and anticonvulsive effectof carbamazepine after cogrinding with microcrystalline cellulose. J. Pharm. Pharm. Sci. 9 (2006) 307-316
23. Liang C.Y., and Marchessault R.H. Infrared spectra of crystalline polysaccharides. J. Polym. Sci. 39 (1959) 269-278
24. Karavas E., Ktistis G., Xenakis A., and Georgarakis E. Miscibility behaviour and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev. Ind. Pharm. 31 (2005) 473-489